Clinical comparison of antibacterial action of sparfloxacin with lomefloxacin

Aim This study aimed at clinical comparative trial of sparfloxacin (SPLX) with lomefloxacin (LMLX). Methods Twenty four patients with bacterial infections in respiratory tract or urinary tract were randomly seperated to two groups of SPLX and LMLX. After administration of 200～300 mg of SPLX once daily or 200～400 mg of LMLX twice daily, the clinical effects were observed and defined as cure, obvious efficiency, effcativeness and no effect. Results Isolation rate of bacteria from patients was 91.7%.Total intake amount of SPLX was significantly less than that of LMLX, but cure rate and effective rate in group SPLX were significantly higher than in group LMLX. There were no adverse drug ractions in both groups. Conclusions SPLX is a safe and effective drug among fluoroquinolones in treatment of bacterial infections. The ratio of effect over dose of sparfloxacin is higher than that of lomefloxacin.